# BillionToOne, Inc.: financial statements, quarterly

BLLN · Nasdaq · CIK 2070849 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/blln.md) · [Financials](/companies/blln/financials.md) · [Filings](/companies/blln/filings.md) · [Insiders](/companies/blln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/blln/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [38.4](/filings/0001628280-25-056321.md) | [45.1 d](/filings/0002070849-26-000017.md) | [59.0](/filings/0002070849-26-000031.md) | [66.6](/filings/0002070849-26-000050.md) | [83.5](/filings/0001628280-25-056321.md) | [96.1 d](/filings/0002070849-26-000017.md) | [108](/filings/0002070849-26-000031.md) | [109](/filings/0002070849-26-000050.md) |
| Cost of revenue | $m | [18.2](/filings/0001628280-25-056321.md) | [19.4 d](/filings/0002070849-26-000017.md) | [21.0](/filings/0002070849-26-000031.md) | [23.1](/filings/0002070849-26-000050.md) | [25.1](/filings/0001628280-25-056321.md) | [27.4 d](/filings/0002070849-26-000017.md) | [29.3](/filings/0002070849-26-000031.md) | [32.3](/filings/0002070849-26-000050.md) |
| Gross profit | $m | [20.2](/filings/0001628280-25-056321.md) | [25.7 d](/filings/0002070849-26-000017.md) | [38.0](/filings/0002070849-26-000031.md) | [43.5](/filings/0002070849-26-000050.md) | [58.4](/filings/0001628280-25-056321.md) | [68.6 d](/filings/0002070849-26-000017.md) | [79.1](/filings/0002070849-26-000031.md) | [77.1](/filings/0002070849-26-000050.md) |
| Research and development | $m | [9.6](/filings/0001628280-25-056321.md) | [11.0 d](/filings/0002070849-26-000017.md) | [10.4](/filings/0002070849-26-000031.md) | [11.8](/filings/0002070849-26-000050.md) | [13.0](/filings/0001628280-25-056321.md) | [14.3 d](/filings/0002070849-26-000017.md) | [14.7](/filings/0002070849-26-000031.md) | [17.3](/filings/0002070849-26-000050.md) |
| Selling, general and administrative | $m | [23.3](/filings/0001628280-25-056321.md) | [26.4 d](/filings/0002070849-26-000017.md) | [29.9](/filings/0002070849-26-000031.md) | [33.3](/filings/0002070849-26-000050.md) | [35.8](/filings/0001628280-25-056321.md) | [44.0 d](/filings/0002070849-26-000017.md) | [46.6](/filings/0002070849-26-000031.md) | [54.3](/filings/0002070849-26-000050.md) |
| Operating income | $m | [(12.6)](/filings/0001628280-25-056321.md) | [(11.7) d](/filings/0002070849-26-000017.md) | [(2.3)](/filings/0002070849-26-000031.md) | [(1.6)](/filings/0002070849-26-000050.md) | [9.6](/filings/0001628280-25-056321.md) | [10.3 d](/filings/0002070849-26-000017.md) | [17.8](/filings/0002070849-26-000031.md) | [5.5](/filings/0002070849-26-000050.md) |
| Interest expense | $m | [0.4](/filings/0001628280-25-056321.md) | [0.0 d](/filings/0002070849-26-000017.md) | [0.0](/filings/0002070849-26-000031.md) | [0.0](/filings/0002070849-26-000050.md) | [0.0](/filings/0001628280-25-056321.md) | [0.0 d](/filings/0002070849-26-000017.md) | [0.0](/filings/0002070849-26-000031.md) | [0.0](/filings/0002070849-26-000050.md) |
| Income tax | $m | [0.0](/filings/0001628280-25-056321.md) | [0.0 d](/filings/0002070849-26-000017.md) | [0.1](/filings/0002070849-26-000031.md) | [0.0](/filings/0002070849-26-000050.md) | [(0.1)](/filings/0001628280-25-056321.md) | [0.3 d](/filings/0002070849-26-000017.md) | [0.5](/filings/0002070849-26-000031.md) | [(0.5)](/filings/0002070849-26-000050.md) |
| Net income | $m | [(14.9)](/filings/0001628280-25-056321.md) | [(11.5) d](/filings/0002070849-26-000017.md) | [(4.0)](/filings/0002070849-26-000031.md) | [(0.2)](/filings/0002070849-26-000050.md) | [5.7](/filings/0001628280-25-056321.md) | [6.0 d](/filings/0002070849-26-000017.md) | [18.0](/filings/0002070849-26-000031.md) | [8.1](/filings/0002070849-26-000050.md) |
| Diluted EPS | $ per share | [(1.47)](/filings/0001628280-25-056321.md) | not reported | [(0.39)](/filings/0002070849-26-000031.md) | [(0.02)](/filings/0002070849-26-000050.md) | [0.10](/filings/0001628280-25-056321.md) | not reported | [0.34](/filings/0002070849-26-000031.md) | [0.15](/filings/0002070849-26-000050.md) |
| Basic EPS | $ per share | [(1.47)](/filings/0001628280-25-056321.md) | not reported | [(0.39)](/filings/0002070849-26-000031.md) | [(0.02)](/filings/0002070849-26-000050.md) | [0.14](/filings/0001628280-25-056321.md) | not reported | [0.39](/filings/0002070849-26-000031.md) | [0.17](/filings/0002070849-26-000050.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [191](/filings/0002070849-26-000017.md) | not reported | not reported | [195](/filings/0001628280-25-056321.md) | [496](/filings/0002070849-26-000050.md) | [537](/filings/0002070849-26-000031.md) | [549](/filings/0002070849-26-000050.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [228](/filings/0002070849-26-000017.md) | not reported | not reported | [252](/filings/0001628280-25-056321.md) | [561](/filings/0002070849-26-000050.md) | [624](/filings/0002070849-26-000031.md) | [651](/filings/0002070849-26-000050.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [302](/filings/0002070849-26-000017.md) | not reported | not reported | [328](/filings/0001628280-25-056321.md) | [633](/filings/0002070849-26-000050.md) | [701](/filings/0002070849-26-000031.md) | [730](/filings/0002070849-26-000050.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [28.4](/filings/0002070849-26-000017.md) | not reported | not reported | [40.8](/filings/0001628280-25-056321.md) | [48.0](/filings/0002070849-26-000050.md) | [57.2](/filings/0002070849-26-000031.md) | [55.7](/filings/0002070849-26-000050.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [134](/filings/0002070849-26-000017.md) | not reported | not reported | [148](/filings/0001628280-25-056321.md) | [153](/filings/0002070849-26-000050.md) | [195](/filings/0002070849-26-000031.md) | [193](/filings/0002070849-26-000050.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | [51.5](/filings/0002070849-26-000017.md) | not reported | not reported | [55.0](/filings/0001628280-25-056321.md) | [57.2](/filings/0002070849-26-000017.md) | [90.0](/filings/0002070849-26-000031.md) | [91.0](/filings/0002070849-26-000050.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0002070849-26-000017.md) | not reported | not reported | not reported | [0.0](/filings/0002070849-26-000017.md) | not reported | not reported |
| Shareholders' equity | $m | [(142)](/filings/0002070849-26-000017.md) | [(219)](/filings/0002070849-26-000017.md) | [(230)](/filings/0001628280-25-056321.md) | [(243)](/filings/0001628280-25-056321.md) | [(252)](/filings/0002070849-26-000050.md) | [(253)](/filings/0002070849-26-000050.md) | [(250)](/filings/0002070849-26-000050.md) | [(240)](/filings/0001628280-25-056321.md) | [480](/filings/0002070849-26-000050.md) | [506](/filings/0002070849-26-000050.md) | [537](/filings/0002070849-26-000050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.4) d](/filings/0002070849-26-000017.md) | [2.6](/filings/0002070849-26-000031.md) | [1.2 d](/filings/0002070849-26-000050.md) | [10.0 d](/filings/0001628280-25-056321.md) | [10.8 d](/filings/0002070849-26-000017.md) | [15.4](/filings/0002070849-26-000031.md) | [9.1 d](/filings/0002070849-26-000050.md) |
| Capital expenditure | $m | [2.1 d](/filings/0002070849-26-000017.md) | [2.3](/filings/0002070849-26-000031.md) | [2.9 d](/filings/0002070849-26-000050.md) | [2.1 d](/filings/0001628280-25-056321.md) | [1.5 d](/filings/0002070849-26-000017.md) | [4.5](/filings/0002070849-26-000031.md) | [4.0 d](/filings/0002070849-26-000050.md) |
| Share repurchases | $m | [0.0 d](/filings/0002070849-26-000017.md) | not reported | not reported | not reported | [0.0 d](/filings/0002070849-26-000017.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.1](/filings/0001628280-25-056321.md) | [10.3](/filings/0002070849-26-000031.md) | [10.4](/filings/0002070849-26-000050.md) | [15.6](/filings/0001628280-25-056321.md) | [53.0](/filings/0002070849-26-000031.md) | [54.5](/filings/0002070849-26-000050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.